Deborah Birx
Known title: DirectorCIK: 0001849673
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Innoviva (INVA) Draws Value Investor Attention Amid Low Valuation. Recent articles highlight Innoviva's low price-to-earnings ratio of 4.3, positioning it as a potential value pick compared to peers like Merck. With the stock trading near its 52-week low, analysts are debating whether the current price reflects undervaluation or persistent risk. The focus on valuation metrics suggests investors are scrutinizing the company's financial appeal rather than recent operational news.
Transaction History
| ARMP | ▼ Sell | Tax Withholding | 14,041 | $60K | 7/10/2026 | View on chart |
| ARMP | ▼ Sell | Tax Withholding | 4,919 | $52K | 3/14/2026 | View on chart |
| ARMP | ▼ Sell | Tax Withholding | 13,637 | $31K | 7/10/2025 | View on chart |
| ARMP | ▼ Sell | Tax Withholding | 6,061 | $12K | 3/14/2025 | View on chart |
| ARMP | ▼ Sell | Tax Withholding | 22,925 | $61K | 7/10/2024 | View on chart |
| ARMP | ▲ Buy | Grant | 60,000 | $0 | 3/14/2024 | View on chart |
| ARMP | ▲ Buy | Grant | 200,000 | $0 | 12/21/2023 | View on chart |
| INVA | ▲ Buy | Grant | 16,495 | $0 | 5/22/2023 | View on chart |
| INVA | ▲ Buy | Grant | 12,647 | $0 | 4/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
Armata Secures $3.7M Pentagon Funding for Phase 3 Trial
Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its anti-bacterial program, AP-SA02. The company also announced it will present data at the ISSSI 2026 conference showing how genetic diversity in AP-SA02 may enhance its effectiveness against certain Staphylococcus aureus isolates. While the stock recently declined following the funding news, analysts have maintained a positive outlook with a price target of $15.
Armata Secures $3.7M Pentagon Funding for Phase 3 Trial. Armata Pharmaceuticals received $3.7 million in non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its anti-bacterial program, AP-SA02. The company also announced it will present data at the ISSSI 2026 conference showing how genetic diversity in AP-SA02 may enhance its effectiveness against certain Staphylococcus aureus isolates. While the stock recently declined following the funding news, analysts have maintained a positive outlook with a price target of $15.